A commercial stage medical device company that manufactures and sells an algae-derived polymer gel used to stop bleeding.

Cresilon currently has products for both veterinary use (VetiGel) and a new first human-use product, TraumaGel, which received FDA 510(k) approval for external use in emergency settings in August 2024. Expansion into human market presents significant upside, starting with external bleeding and scaling up the more lucrative trauma & surgical markets. Cresilon's competitive advantage stems from its unique manufacturing capabilities & its product's ability to quickly control bleeding across various settings. Funds will be used to purchase lab and office fixtures and fittings needed to expand production and corporate activities for a 2025 commercial launch of TraumaGel.